Lipoprotein(a) (Lp[a]) levels are genetically mediated and considered to be causal in the development of atherosclerotic cardiovascular disease (ASCVD).
1,2 Although reducing low-density lipoprotein cholesterol levels remains the dominant means of attenuating ASCVD risk, substantial residual risk despite established therapies has led to the effort to identify novel biomarkers and treatment targets.
3 Lipoprotein(a) has thus emerged as a potential therapeutic target, with antisense oligonucleotides directed specifically at hepatocytes demonstrating substantial 70% to 90% reductions in circulating Lp(a) levels in early-phase clinical trials in humans.
4 Despite these recent advances, it remains unclear which patient populations would benefit the most from Lp(a) reduction, and what degree of Lp(a) lowering would be required to demonstrate incremental clinical benefit despite the use of background established medical therapies.
5,6